Shelton Capital Management’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-74,850
| Closed | -$3.04M | – | 732 |
|
|
2022
Q4 | $3.04M | Sell |
74,850
-57,000
| -43% | -$2.32M | 0.32% | 108 |
|
|
2022
Q3 | $8.62M | Sell |
131,850
-18,150
| -12% | -$1.19M | 0.41% | 62 |
|
|
2022
Q2 | $9.12M | Hold |
150,000
| – | – | 0.41% | 62 |
|
|
2022
Q1 | $9.42M | Hold |
150,000
| – | – | 0.35% | 69 |
|
|
2021
Q4 | $11.4M | Buy |
150,000
+28,000
| +23% | +$2.12M | 0.4% | 52 |
|
|
2021
Q3 | $13.7M | Buy |
122,000
+34,000
| +39% | +$3.81M | 0.53% | 37 |
|
|
2021
Q2 | $14.2M | Buy |
88,000
+8,000
| +10% | +$1.3M | 0.54% | 36 |
|
|
2021
Q1 | $9.75M | Buy |
80,000
+42,700
| +114% | +$5.2M | 0.34% | 64 |
|
|
2020
Q4 | $5.71M | Buy |
37,300
+5,300
| +17% | +$811K | 0.26% | 78 |
|
|
2020
Q3 | $2.68M | Hold |
32,000
| – | – | 0.11% | 199 |
|
|
2020
Q2 | $2.35M | Hold |
32,000
| – | – | 0.13% | 152 |
|
|
2020
Q1 | $1.36M | Buy |
32,000
+9,000
| +39% | +$382K | 0.1% | 182 |
|
|
2019
Q4 | $1.4M | Buy |
23,000
+1,000
| +5% | +$60.9K | 0.08% | 201 |
|
|
2019
Q3 | $902K | Hold |
22,000
| – | – | 0.05% | 235 |
|
|
2019
Q2 | $1.04M | Buy |
22,000
+21,382
| +3,460% | +$1.01M | 0.06% | 228 |
|
|
2019
Q1 | $17.3K | Sell |
618
-12,182
| -95% | -$341K | 0.07% | 251 |
|
|
2018
Q4 | $366K | Buy |
12,800
+5,300
| +71% | +$152K | 0.02% | 393 |
|
|
2018
Q3 | $333K | Hold |
7,500
| – | – | 0.02% | 534 |
|
|
2018
Q2 | $441K | Buy |
+7,500
| New | +$441K | 0.03% | 394 |
|